Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Specialty Chemicals

Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. In addition, it operates Balaji Sarovar Premiere, a hotel in Solapur, Maharashtra, as well as engages in the provision of hotel, restaurant, and hospitality services. The company serves pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning chemical, dye and textile, pesticides and insecticides, water treatment chemical, optical brighteners, corrosion inhabitations, cosmetics, explosives, and foundry chemicals industries. It also exports its products to the United States, the United Kingdom, Argentina, Latin America, Canada, Israel, Australia, Bangladesh, Germany, Italy, Egypt, South Africa, and internationally. Balaji Amines Limited was incorporated in 1988 and is headquartered in Solapur, India.

Revenue projections:

Revenue projections for BALAMINES
Revenue projections for BALAMINES

BALAMINES's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 20.664606
debtToEquity 1.530000
earningsGrowth -0.073000
revenueGrowth 0.059000
grossMargins 0.433780
operatingMargins 0.128280
trailingEps 44.410000
forwardEps 64.700000

BALAMINES's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
With both earnings and revenue growth in low territory, BALAMINES is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
Balaji Amines Limited's negative gross and operating margins reflect unprofitability, suggesting the company is unable to generate revenue sufficient to cover its costs. This could indicate deeper financial challenges or declining efficiency.
BALAMINES's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Price projections for BALAMINES
Price projections for BALAMINES

Over time, Balaji Amines Limited's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.

Recommendation changes over time:

Recommendations trend for BALAMINES
Recommendations trend for BALAMINES


The analysts have presented a mixed picture of BALAMINES, with no clear buy or sell ratings. This uncertainty indicates that investors may need to look beyond analyst opinions and explore other factors to make well-rounded decisions about investing in the stock.